ReviewPathogens (Basel, Switzerland)2024
Group A Streptococcus Infections in Children: Epidemiological Insights Before and After the COVID-19 Pandemic.
Review in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Temporal trends in pediatric group A streptococcal pharyngitis across the coronavirus disease 2019 era: A large retrospective cohort study.The Journal of international medical research · 2026Article
- Post-pandemic immunity debt for paediatric infectious diseases in Japan between 2014 and 2024.Epidemiology and infection · 2026Observational
- Carbon metabolism and niche adaptation inmSphere · 2026Review
- Clinical features and trends of severe paediatric group A streptococcal infections in Japan in the post-COVID-19 pandemic era.Epidemiology and infection · 2026Article
- Beyond COVID-19: meeting the challenge of evolving pediatric invasive group A streptococcal disease.Clinical and experimental pediatrics · 2025Article
- Old Bug, New Challenge: Invasive Group A Streptococcus and a Rare Pediatric Holospinal Epidural Abscess.Cureus · 2025Article
- Evolving treatment strategies for invasive Streptococcus pyogenes in children in the postpandemic era.Clinical and experimental pediatrics · 2025Article
- Molecular Characterization ofMicroorganisms · 2025Article
- Characterization ofMicroorganisms · 2025Article
- Post-pandemic upsurge of group A streptococcus infections: potential link to impaired herd trained immunity following COVID-19 lockdowns.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group A streptococcus (GAS) is the cause of both mild and invasive infections in humans with a high morbidity and mortality rate. The transmission of disease usually occurs via droplets, so the implementation of infection mitigation strategies (IMS) during the COVID-19 pandemic altered the incidence of GAS infection. This review aims to provide an overview of the influence of the COVID-19 pandemic on the incidence of GAS infection in children (invasive or non-invasive). A surge in the incidence of invasive GAS infection was noted in December 2022 after the reversal of IMS. A global uprise in GAS infection (invasive and non-invasive) was noted, especially concerning the pediatric population. Children younger than 5 years old were mostly affected, with complicated pneumonia being the leading clinical manifestation, causing many deaths worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.